BackNewAmsterdam Pharma Company NV Overview

NewAmsterdam Pharma Company NV Long Term Debt

Track NewAmsterdam Pharma Company NV's long-term debt ($56K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$56000.00
72.82% YoYΔ $-150000.00 vs prior year quarter

Peer trimmed avg / median

Loading

NewAmsterdam Pharma Company NV Long Term Debt History

Loading

NewAmsterdam Pharma Company NV vs. peers: Long Term Debt Comparison

Loading

NewAmsterdam Pharma Company NV Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

NewAmsterdam Pharma Company NV (NAMS) FAQ

As of the most recent data (June 2026), NAMS shows a long-term debt of $56K. That compares with $210K in the prior-year period — down 72.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NAMS's long-term debt is now $56K (was $210K) — a 72.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether NewAmsterdam Pharma Company NV is outperforming or lagging.

Tracking NAMS's long-term debt over time shows whether NewAmsterdam Pharma Company NV is scaling, shrinking, or reshaping that part of the business. The current reading is $56K That compares with $210K in the prior-year period — down 72.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has NewAmsterdam Pharma Company NV's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $56K) with ownership activity and broader fundamentals.